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The National Alopecia Areata Registry (NAAR) was estab-
lished as a collaborative effort of five academic centers and
was funded by the NIAMS (National Institute of Arthritis and
Musculoskeletal and Skin Diseases) on 23 September 2000
and now has been transferred to the National Alopecia Areata
Foundation (NAAF). The NAAR has an internet domain and
website http://www.alopeciaareataregistry.com, which allows
patients to self-register in the first tier. Patients were then
invited to one of the five centers to have an examination and
blood was drawn for samples of DNA, sera, and lymphoblast
lines to be used for genetic studies. This will update the
progress of the NAAR over the past 10 years and its emergence
as a clinical trials network and biobank.
At the time of the Summit, 6,153 of the 8,942 first-tier
registrants had dermatologist-confirmed alopecia areata (AA),
including 2,202 with alopecia areata persistent (AAP)41 year,
2,142 with alopecia universalis AU, 897 with alopecia totalis
(AT), and 823 with transient AA (AAT)o1 year. There were
2,609 AA patients examined in tier 2, including 729 with AAP,
526 with AAT, 339 with AT, and 1,015 with AU as well as
396 unrelated controls and 463 related but unaffected. The
distribution of age of onset is shown in Figure 1. We have
identified 264 multiplex families and acquired 40 for linkage
analysis.
The Registry has been used for a number of projects relating
to the pathogenesis and quality of life: (1) confirming the
reported human leukocyte antigen associations; (2) studies of
cytokine profiles in AA with or without atopy; (3) case-control
study—incidence of autoimmunity in AA patients; (4) EBV
(Epstein–Barr virus) as a trigger for AA in adolescents; (5)
treatment practices in AA; (6) quality of life in adolescents and
adults with AA; (7) self-reported trigger factors for AA; and last
but not least (8) association and linkage studies—genome-
wide association studies revealing eight novel genes asso-
ciated with AA that have been confirmed and being translated
into clinical trials.
The NAAR continues to accept patient registrations. NAAR
is involved in an NIH (National Institutes of Health)-funded
biomarker study to acquire scalp biopsies and DNA samples.
The five centers in the Registry (University of Texas MD
Anderson Cancer Center; Columbia University; University of
Minnesota; University of Colorado; University of California,
San Francisco) are a consortium for clinical trials, and the
Registry sample collection represents an existing biobank for
future translational studies.
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Figure 1. Age distribution of onset of alopecia areata. AU, alopecia
universalis; AT, alopecia totalis; AAP, alopecia areata persistent, duration
41 year; AAT1 and 2, alopecia areata transient—1 is duration o6 months,
2 is duration 6 months to 1 year.
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